US Measles Cases Top 5,000 for First Time in 35 Years

The return of measles at this scale is a public-health story with real market read-through for vaccine makers and for any sector that depends on stable public-health infrastructure. It also tests how quickly health authorities can rebuild confidence in routine immunization after years of declining coverage. Whether this year's total proves an outlier or the start of a sustained pattern is the open question, and it will shape how vaccine demand and public-health funding are viewed going forward.